An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation

References

• Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675–1688. doi:10.1016/S0140-6736(20)31548-8
   PubMed Web of Science ®Google Scholar
• Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407. doi:10.1053/j.gastro.2016.02.031
   Web of Science ®Google Scholar
• Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17–44. doi:10.14309/ajg.0000000000001036
   PubMed Web of Science ®Google Scholar
• Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917. doi:10.1016/S2468-1253(20)30217-X
   PubMed Web of Science ®Google Scholar
• Staller K, Olén O, Söderling J, et al. Mortality risk in irritable bowel syndrome: results from a nationwide, prospective cohort study. Am J Gastroenterol. 2020;115(5):746–755. doi:10.14309/ajg.0000000000000573
   PubMed Web of Science ®Google Scholar
• Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-related quality of life in irritable bowel syndrome: a systematic review and meta-analysis. Gastroenterol Nurs. 2020;43(3):E102–E122. doi:10.1097/SGA.0000000000000530
   PubMed Web of Science ®Google Scholar
• Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: exploring mediating factors through structural equation modelling. J Psychosom Res. 2022;159:110809. doi:10.1016/j.jpsychores.2022.110809
   PubMed Web of Science ®Google Scholar
• Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17(12):2471–2478 e2473. doi:10.1016/j.cgh.2019.08.016
   PubMed Web of Science ®Google Scholar
• Singh P, Staller K, Barshop K, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103–8109. doi:10.3748/wjg.v21.i26.8103
   PubMed Web of Science ®Google Scholar
• Lacy BE, Parikh M, Taylor DCA, et al. Prevalence and impact of abdominal symptoms in patients with IBS-C. Am J Gastroenterol. 2021;116(1):S229–S230. doi:10.14309/01.ajg.0000774524.77992.13
   PubMedGoogle Scholar
• Yu V, Ballou S, Hassan R, et al. Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders. Am J Gastroenterol. 2021;116(8):1720–1726. doi:10.14309/ajg.0000000000001306
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):580–587. doi:10.1038/ajg.2015.67
   PubMed Web of Science ®Google Scholar
• Fehnel SE, Ervin CM, Carson RT, et al. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health. 2017;20(4):618–626. doi:10.1016/j.jval.2016.11.001
   PubMed Web of Science ®Google Scholar
• Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022;163(1):118–136. doi:10.1053/j.gastro.2022.04.016
   PubMed Web of Science ®Google Scholar
• Mearin F, Ciriza C, Minguez M, et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363. doi:10.17235/reed.2016.4389/2016
   PubMed Web of Science ®Google Scholar
• Schoenfeld PS. Advances in IBS 2016: a review of current and emerging data. Gastroenterol Hepatol. 2016;12(8 Suppl 3):1–11.
   Google Scholar
• Quigley EMM, Horn J, Kissous-Hunt M, Crozier RA, Harris LA. Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018;35(7):967–980. doi:10.1007/s12325-018-0733-x
   PubMed Web of Science ®Google Scholar
• Taylor DCA, Abel JL, Martin C, et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR). J Med Econ. 2020;23(10):1072–1083. doi:10.1080/13696998.2020.1799816
   PubMed Web of Science ®Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1–mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150(4):875–887. doi:10.1053/j.gastro.2015.12.034
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775–G785. doi:10.1152/ajpgi.00155.2012
   PubMed Web of Science ®Google Scholar
• Zhang L, Song J, Hou X. Mast cells and irritable bowel syndrome: from the bench to the bedside. J Neurogastroenterol Motil. 2016;22(2):181–192. doi:10.5056/jnm15137
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang B, Verne NG. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1):41–46. doi:10.1016/j.pain.2009.06.017
   PubMed Web of Science ®Google Scholar
• Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201. doi:10.1136/gut.2007.140806
   PubMed Web of Science ®Google Scholar
• Buhner S, Braak B, Li Q, et al. Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity. Exp Physiol. 2014;99(10):1299–1311. doi:10.1113/expphysiol.2014.080036
   PubMed Web of Science ®Google Scholar
• Deiteren A, de Wit A, van der Linden L, De Man JG, Pelckmans PA, De Winter BY. Irritable bowel syndrome and visceral hypersensitivity: risk factors and pathophysiological mechanisms. Acta Gastroenterol Belg. 2016;79(1):29–38.
   PubMed Web of Science ®Google Scholar
• Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22(4):558–574. doi:10.5056/jnm16001
   PubMed Web of Science ®Google Scholar
• Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Evaluation of colonic sensory thresholds in IBS patients using a barostat: definition of optimal conditions and comparison with healthy subjects. Dig Dis Sci. 1994;39(3):449–457. doi:10.1007/BF02088327
   PubMed Web of Science ®Google Scholar
• Kuiken SD, Lindeboom R, Tytgat GN, Boeckxstaens GE. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(2):157–164. doi:10.1111/j.1365-2036.2005.02524.x
   PubMed Web of Science ®Google Scholar
• Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109(1):40–52. doi:10.1016/0016-5085(95)90267-8
   PubMed Web of Science ®Google Scholar
• Roberts C, Albusoda A, Farmer AD, Aziz Q. Factors influencing rectal hypersensitivity in irritable bowel syndrome: a systematic review and meta‐analysis. Neurogastroenterol Motil. 2023;35(4):e14515. doi:10.1111/nmo.14515
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology. 1990;98(5 Pt 1):1187–1192. doi:10.1016/0016-5085(90)90332-U
   PubMed Web of Science ®Google Scholar
• Mayer EA, Labus J, Aziz Q, et al. Role of brain imaging in disorders of brain–gut interaction: a Rome Working Team Report. Gut. 2019;68(9):1701–1715. doi:10.1136/gutjnl-2019-318308
   PubMed Web of Science ®Google Scholar
• Barbara G, Cremon C, De Giorgio R, et al. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Current Gastroenterol Reports. 2011;13(4):308–315. doi:10.1007/s11894-011-0195-7
   PubMedGoogle Scholar
• Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57(7):923–929. doi:10.1136/gut.2007.138982
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Facer P, Dyer NHC, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 2001;357(9265):1338–1339. doi:10.1016/S0140-6736(00)04503-7
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–824. doi:10.1038/39807
   PubMed Web of Science ®Google Scholar
• Jones RCW, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci. 2005;25(47):10981–10989. doi:10.1523/JNEUROSCI.0703-05.2005
   PubMed Web of Science ®Google Scholar
• Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007;132(2):615–627. doi:10.1053/j.gastro.2006.11.014
   PubMed Web of Science ®Google Scholar
• Wiskur BJ, Tyler K, Campbell-Dittmeyer K, Chaplan SR, Wickenden AD, Greenwood-Van Meerveld B. A novel TRPV1 receptor antagonist JNJ-17203212 attenuates colonic hypersensitivity in rats. Methods Find Exp Clin Pharmacol. 2010;32(8):557–564. doi:10.1358/mf.2010.32.8.1507853
   PubMedGoogle Scholar
• Keszthelyi D, Troost FJ, Jonkers DM, et al. Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation? Eur J Pain. 2013;17(9):1299–1306. doi:10.1002/j.1532-2149.2013.00309.x
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010;59(6):767–774. doi:10.1136/gut.2009.194449
   PubMed Web of Science ®Google Scholar
• Crouzet L, Gaultier E, Del’Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil. 2013;25(4):e272–e282. doi:10.1111/nmo.12103
   PubMed Web of Science ®Google Scholar
• Buhner S, Li Q, Berger T, et al. Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil. 2012;24(12):1134–e1572. doi:10.1111/nmo.12011
   PubMed Web of Science ®Google Scholar
• Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137(4):1425–1434. doi:10.1053/j.gastro.2009.07.005
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702. doi:10.1053/j.gastro.2003.11.055
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37. doi:10.1053/j.gastro.2006.11.039
   PubMed Web of Science ®Google Scholar
• Grabauskas G, Wu X, Gao J, Li JY, Turgeon DK, Owyang C. Prostaglandin E(2), produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice. Gastroenterology. 2020;158(8):2195–2207 e2196. doi:10.1053/j.gastro.2020.02.022
   PubMed Web of Science ®Google Scholar
• Lyons DO, Pullen NA. Beyond IgE: alternative mast cell activation across different disease states. Int J Mol Sci. 2020;21(4):1498. doi:10.3390/ijms21041498
   PubMed Web of Science ®Google Scholar
• Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: a systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine. 2017;99:132–138. doi:10.1016/j.cyto.2017.08.017
   PubMed Web of Science ®Google Scholar
• Buckley MM, O’Halloran KD, Rae MG, Dinan TG, O’Malley D. Modulation of enteric neurons by interleukin‐6 and corticotropin‐releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome. J Physiol. 2014;592(23):5235–5250. doi:10.1113/jphysiol.2014.279968
   PubMed Web of Science ®Google Scholar
• O’Malley D, Liston M, Hyland NP, Dinan TG, Cryan JF. Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2011;300(2):G241–G252. doi:10.1152/ajpgi.00385.2010
   PubMed Web of Science ®Google Scholar
• Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A Phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407–416. doi:10.1007/s10157-016-1302-8
   PubMed Web of Science ®Google Scholar
• Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig. 2018;38(4):341–351. doi:10.1007/s40261-017-0614-0
   PubMed Web of Science ®Google Scholar
• Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):227ra236. doi:10.1126/scitranslmed.3007790
   Web of Science ®Google Scholar
• Nikolovska K, Seidler UE, Stock C. The role of plasma membrane sodium/hydrogen exchangers in gastrointestinal functions: proliferation and differentiation, fluid/electrolyte transport and barrier integrity. Front Physiol. 2022;13:899286. doi:10.3389/fphys.2022.899286
   PubMed Web of Science ®Google Scholar
• Gawenis LR, Stien X, Shull GE, et al. Intestinal NaCl transport in NHE2 and NHE3 knockout mice. Am J Physiol Gastrointest Liver Physiol. 2002;282(5):G776–G784. doi:10.1152/ajpgi.00297.2001
   PubMed Web of Science ®Google Scholar
• King AJ, Chang L, Li Q et al. (2024). NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons. Am J Physiol Gastrointest Liver Physiol. 2024. doi:10.1152/ajpgi.00233.2023
   Google Scholar
• King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):eaam6474. doi:10.1126/scitranslmed.aam6474
   PubMed Web of Science ®Google Scholar
• Li Q, King AJ, Liu L, Zhu Y, Caldwell JS, Pasricha PJ. Tenapanor reduces IBS pain through inhibition of TRPV1-dependent neuronal hyperexcitability in vivo. Am J Gastroenterol. 2017;112:S255. doi:10.14309/00000434-201710001-00484
   Web of Science ®Google Scholar
• Wang J, Larauche M, Siegel M, et al. Tenapanor attenuates increased macromolecule permeability in human colon monolayer cultures induced by inflammatory cytokines and human fecal supernatants. Gastroenterology. 2018;154(Suppl 1):S326. doi:10.1016/S0016-5085(18)31424-0
   Google Scholar
• Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281–293. doi:10.14309/ajg.0000000000000516
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294–1303. doi:10.14309/ajg.0000000000001056
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Chey WD, Harris LA, et al. Abdominal symptom improvement during clinical trials of tenapanor in patients with irritable bowel syndrome with constipation: a post hoc analysis. Am J Gastroenterol. 2024. doi:10.14309/ajg.0000000000002685
   PubMedGoogle Scholar
• Lembo AJ, Friedenberg KA, Fogel RP, et al. Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO −3 study. Neurogastroenterol Motil. 2023;35(11):e14658. doi:10.1111/nmo.14658
   PubMed Web of Science ®Google Scholar
• IBSRELA (Tenapanor) Tablets [Prescribing Information]. Waltham, MA: Ardelyx, Inc.; 2022.
   Google Scholar
• Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2(1):16014. doi:10.1038/nrdp.2016.14
   PubMedGoogle Scholar